Abstract: A protein called PA binding protein has been isolated which binds specifically and reversibly to tissue plasminogen activator. The protein is characterized by a molecular mass of about 100,000 daltons, and electrophoretic mobility in agarose at pH 8.6 equal to that of plasma .beta.-globulins and an isoelectric point of 6.5 to 7.0. The protein is thermostable up to at least 56.degree. C. and is cleared from the circulation with a half life on the order of days.

Abstract: Monoclonal antibodies specific for the high affinity (72 K.D.) F.sub.c receptor on human monocytes are diclosed. The monoclonal antibodies do not block normal IgG binding to the receptor.

Abstract: A new method for producing live, attenuated rotavirus strains suitable for preparing a vaccine is described. It is demonstrated that a naturally attenuated rotavirus recovered from newborns or other individuals whos have undergone asymptomatic infection can be used for immunization or that a virulent rotavirus can be converted into an attenuated strain by substituting the conserved fourth rotavirus gene segments of a naturally attenuated rotavirus in the genome of the virulent rotavirus.

Abstract: Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. For some of these compositions, an enhanced or potentiated efficacy is observed when the conjugates are administered along with a related, unconjugated monoclonal antibody.Hybridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively. Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.

Abstract: Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the A-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the A-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the A-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.

Abstract: Hybridomally produced monoclonal IgM antibodies having high affinity are useful for the immunoassay and purification of viral antigens.

Abstract: A process for the detection of antibodies to HTLV III/LAV comprising:(A) mixing an unknown serum sample with a crude HTLV III/LAV viral antigen selected from the group consisting of(1) an antigen comprising P24 core protein and Penv protein;(2) a P24 antigen and(3) a Penv antigen,(B) incubating the resultant mixture from step (A);(C) contacting the mixture of step (B) with a solid substrate coated with antibody to HTLV III/LAV;(D) incubating the mass from step (C);(E) washing the mass from step (D);(F) contacting the mass from step (E) with a labeled antibody to HTLV III/LAV;(G) incubating the mass from step (F);(H) washing the mass from step (G);(I) assaying the label in the mass from step (H);(J) as a negative control, mixing a serum sample known to be negative to HTLV III/LAV antibody with a diluent;(K) subjecting the mass from step (J) to steps (B) to (I);(L) as a positive control, mixing a predetermined amount of the crude HTLV III/LAV viral antigen and the diluent;(M) subjecting the mass from step (L) t

Abstract: A specific hybridoma cell line produces monoclonal antibodies which are effective in detecting carcinoembryonic antigens (CEA). The specific hydribome line and monoclonal antibodes are designated as T84.66-A3.1-H11. The monoclonal antibodies are preferably applied to tissues and fluids to detect the degree of binding of such monoclonal antibodies to such carcinoembryonic antigens.

Abstract: This invention relates to the production of recombinant proteins in mammals' milk. Particularly, this invention relates to an expression system comprising the mammal's casein promoter which when transgenically incorporated into a mammal permits the female species of that mammal to produce the desired recombinant protein in or along with its milk. This invention also relates to the transgenic mammal that produces the desired recombinant product in its milk.

Abstract: The present invention provides a lymphocyte-mediated immunotherapy for the treatment of human or animal subjects afflicted with abnormal or tumor cells which express a MHC Class II antigen on their surface. The method utilizes inducer T-cell clones or lines having a demonstrable specificity for an identifiable antigen. These T-cells are activated in-vivo to express cytolytic and therapeutic activity against the abnormal or tumor cells in the subject.

Abstract: The present invention provides a novel hybridoma cell line secreting monoclonal antibodies (MoAbs) that define an epitope found on an antigen of the classification termed CEA/NCA (carcinoembryonic antigen/normal cross-reacting antigen). The MoAbs of the invention find particular utility as the targeting moiety of immunotoxin and immunoimaging conjugates.Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.

Abstract: This invention relates to the production of antibodies to angiogenin or to fragments thereof and to methods of inhibiting angiogenesis in mammals by administering to mammals such antibodies or Fab fragments thereof so as to inhibit angiogenic activity. In addition, this invention relates to pharmaceutical compositions comprising therapeutically effective amounts of antibody that are immunologically reactive with angiogenin and which can be administered to inhibit angiogenesis.

Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are reactive with ganglioside antigens GD2 and GD3 and are essentially non-reactive with other ganglioside antigens. The invention further relates to methods of using these antibodies.

Abstract: A method and composition for killing target cells is disclosed. The method utilizes ex vivo IL-2 activation of leucocyte effector cells and arming the activated leucocyte effectors with monoclonal antibodies whose Fc portions bind to the IL-2-activated effectors and whose paratopic portions immunoreact with an epitope expressed on the surfaces of the target cells. The composition contains a cytolytic amount of the armed, IL-2-activated effector cells dispersed in an aqueous physiologically tolerable diluent medium.

Abstract: A conjugate comprising a vinca moiety convalently linked at the 4-position via a group of the formula --OCOXCO-- where X represents a single chemical bond or an optionally substituted C.sub.1-10 chain, to an immunoglobulin or an immunoglobulin fragment.The conjugates are useful in the treatment of cancer.

Abstract: An improvement in a method to conjugate a protein which must resist denaturation with a variable component using a carbodiimide condensing agent utilizes a polar aprotic solvent as the medium for condensation. This improvement results in shorter reaction times and improved coupling efficiency.

Abstract: A method of preparing remedies for the treatment of bacterial and viral infections which involves introduction into the udder of an ungulate during lactation, a specific vaccine comprising bacterial and/or viral organisms in an inactive state, and the preparation of small dosages of the secretary fluid subsequently withdrawn during lactation from the ungulate thus treated.

Abstract: Method and composition for providing a non-toxic, sterile, virally inactivated human transferrin preparation for use in cell culture systems. The method comprises saturation of the transferrin with an excess of iron, removal of free iron radicals and unwanted proteins, and pasteurization of the iron-bound transferrin substantially free of iron radicals.

Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.

Abstract: This invention relates to a hydrated adhesive gel using a product which is obtained by reacting an aqueous solution consisting essentially of protein having amino groups at the side chains thereof, a gelling retarder, and a hydrophilic tackifier with a N-hydroxyimidoester compound.